Condition: Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · T - Cell Lymphoma · PTCL · Sponsor: Peking University People's Hospital
To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL
This description comes directly from the study's public registry record.
MENG LV, MD PhD · +861088324637 · drlvmeng@bjmu.edu.cn
Always discuss trial participation with your own doctor first.
| Peking University People's Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06874946